bioMerieux (OTCMKTS:BMXMF) Stock Passes Below 50-Day Moving Average – Here’s What Happened

bioMerieux (OTCMKTS:BMXMF)’s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $104.81 and traded as low as $84.4136. bioMerieux shares last traded at $84.4136, with a volume of 119 shares trading hands.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on BMXMF shares. Deutsche Bank Aktiengesellschaft cut shares of bioMerieux from a “buy” rating to a “hold” rating in a report on Friday, April 24th. Zacks Research raised shares of bioMerieux to a “hold” rating in a report on Tuesday, April 28th. Finally, BNP Paribas Exane cut shares of bioMerieux to a “neutral” rating in a report on Wednesday, January 28th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has an average rating of “Hold”.

bioMerieux Stock Performance

The business’s 50-day moving average is $104.81 and its two-hundred day moving average is $116.49. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.